Earendil Labs, Sanofi Ink Global License Deal for Next-Gen Autoimmune Therapies
April 18, 2025 | 16:23
Earendil Labs and Sanofi today announced that they have entered into a license agreement for two potential first-in-class bispecific antibodies in the field of autoimmune and inflammatory bowel diseases.
Mobile Version